Describing Clinical Characteristics and Treatment Course of Patients with Hereditary Alpha-tryptasemia: A Single-center Study
- PMID: 40515774
- DOI: 10.1007/s12016-025-09063-0
Describing Clinical Characteristics and Treatment Course of Patients with Hereditary Alpha-tryptasemia: A Single-center Study
Abstract
Patients with hereditary alpha-tryptasemia (HαT) have been shown not only to be more prone to anaphylaxis but also to more severe reactions. The relationship between hypermobility, gastroparesis, gastroesophageal reflux disease (GERD), postural orthostatic tachycardia syndrome (POTS), and HαT has been variably described in the literature although no causal biochemical or genetic link has been identified. Herein, we sought to describe the clinical presentation, treatment, and co-morbidities of patients diagnosed with HαT within the Penn State Health System. Through a retrospective cross-sectional chart review, we report the clinical and therapeutic characteristics of patients who tested positive for HαT genotypes (2α3β, 3α2β) within Penn State Health. Twenty-six percent of patients within our cohort had co-occurring diagnoses of hypermobility (7, 26.9%), or POTS (7, 26.9%) while more than half of patients had GERD (15, 57.7%). Anaphylaxis was reported among 7 (26.9%) with the average number of anaphylactic episodes per patient prior to HαT identification being less than one. Patients with triplication had higher prevalence of hypermobility and POTS and were more likely to receive treatment with omalizumab or cromolyn. Co-morbid hypermobility, POTS and GERD in patients with flushing, urticaria, or anaphylaxis should warrant further investigation for HαT.
Keywords: Anaphylaxis; Hereditary alpha-tryptasemia; Tryptase; Urticaria.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Lyons JJ et al (2016) “Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number,” (in eng). Nat Genet 48(12):1564–1569. https://doi.org/10.1038/ng.3696 - DOI - PubMed - PMC
-
- von Bubnoff D, Koch D, Stocker H, Ludwig RJ, Wortmann F, von Bubnoff N (2024) “The Clinical Features of Hereditary Alpha-Tryptasemia,” (in eng). Dtsch Arztebl Int 121(8):258–264. https://doi.org/10.3238/arztebl.m2023.0287 - DOI
-
- Lyons JJ (2018) “Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features,” (in eng). Immunol Allergy Clin North Am 38(3):483–495. https://doi.org/10.1016/j.iac.2018.04.003 - DOI - PubMed - PMC
-
- Robey RC et al (2020) “Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression,” (in eng). J Allergy Clin Immunol Pract 8(10):3549–3556. https://doi.org/10.1016/j.jaip.2020.05.057 - DOI - PubMed
-
- Glover SC et al (2021) “Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond,” (in eng). Ann Allergy Asthma Immunol 127(6):638–647. https://doi.org/10.1016/j.anai.2021.08.009 - DOI - PubMed - PMC
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
